I am a board-certified medical oncologist who works as part of a multidisciplinary team to treat patients with prostate cancer and other genitourinary malignancies. My primary focus is on the medical treatment of men with advanced or high-risk prostate cancer. In addition to using standard therapies, I develop and design clinical trials testing new agents directed at androgen receptor signaling and other molecular pathways of disease progression.
On a national level, I am the site Principal Investigator at MSK for the Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. I am also an expert panel member on the American Society of Clinical Oncology (ASCO) Clinical Guidelines Committee and serve as co-chair of the ASCO Genitourinary Guidelines Advisory Group.
- Clinical Expertise: Prostate Cancer; Other Genitourinary Cancers; Clinical Trials
- Languages Spoken: English
- Education: MD, Tulane School of Medicine
- Residencies: New York University Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Dana E. Rathkopf
- A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
- A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
- A Phase III Study of Abiraterone/Prednisone with JNJ-56021927 or a Placebo in Metastatic Castration-Resistant Prostate Cancer that Has Not Been Treated with Chemotherapy
- A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
- A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer